Conno Christou did everything right. At 35, building his second company, he tracked his sleep with a Whoop band, cross-referenced it with an Oura ring, and submitted to nearly 100 biomarker tests every year. He followed protocols from longevity researchers Peter Attia and Rhonda Patrick, optimized his supplements, circadian rhythm, and protein intake. His 2025 checkup was the best he had in years. Then, after a workout, his arm swelled.
A week later, doctors found two blood clots in his veins. During pre-surgery exams, they discovered an 11-by-11-by-8 centimeter mass behind his sternum. Biopsy confirmed an aggressive form of non-Hodgkin’s lymphoma — a rare diagnosis affecting roughly one in 420,000 people, caused by a random genetic mutation with no connection to lifestyle. The tumor had existed for only about three months. In three more weeks, it would have reached stage four.
“Lucky in my unluckiness,” Christou told this editor from his home in Athens. “It was only found because I went in for something else entirely.”
When two world-class doctors disagree
Christou’s first oncologist, a renowned specialist, recommended the lighter of two available chemotherapy regimens. He booked his first infusion three days out. The night before, he sought a second opinion. That doctor recommended the harder regimen — continuous in-hospital infusion, cycling every three weeks across six months — citing Christou’s specific pathology. The lighter treatment carried roughly a 60% success rate for his presentation. The aggressive one brought that number to around 85%.
Two world-class doctors. Diametrically opposite recommendations.
“As founders, we hold the wheel,” Christou said. “You hear many things. You don’t have to follow the first advice.”
He didn’t stop at two opinions. Over the next two days, he gathered 12 opinions in total — reaching out to hematologists and oncologists in the US and abroad, calling in every favor he could. Eleven to one voted in favor of the harder path. He took it.
Treating chemotherapy like a startup sprint
Over six months of treatment, Christou approached chemotherapy the way he approached building a company — as a marathon of sprints, each with a finite cycle and each week filled with data points. He borrowed from his mandatory 25-month military service in Cyprus, too. He was going to be a good soldier. Trust the process. Six cycles. Get through it.
He wore his Whoop throughout and found it remarkably accurate at predicting the days his immune system would bottom out, sometimes flagging them before symptoms arrived. He kept a symptom journal using voice transcription, logging every shift, every side effect, every medication and counter-medication. He narrowed his focus to three variables: sleep, nutrition, and, first and foremost, psychology.
“It moves the needle more than anything,” Christou said. “I never asked ‘why me’ — not once. That question has no useful answer.”
How AI became a second-opinion engine
Christou fed all of it — blood results, scan data, wearable output, journal entries — into Claude. A public opinion poll released in March found that a third of American adults now use chatbots for health information and advice. Experts urge caution; Danielle Bitterman, clinical lead for data science and AI at Mass General Brigham, has told the New York Times that general-purpose chatbots are frequently wrong and “have not been thoroughly evaluated” for personalized diagnoses.
Christou doesn’t disagree. “It didn’t replace the doctors,” he said, but it “helped me ask the right questions.” For a condition as rare as his — one an oncologist might see once a year — access to a model that had absorbed the full body of medical literature was, he said, simply not the same as a Google search.
The model proved critical at the end of treatment. His final PET scan came back ambiguous. His oncologist began discussing a second line of therapy, potentially radiotherapy near his heart and lungs. Christou again did his homework. He read that for this specific lymphoma, the false-positive rate on end-of-treatment PET scans is around 60% — a statistic that still astonishes him.
He fed all three of his PET scans and his MRI into Claude, which flagged a known but easily overlooked phenomenon: in patients under 40 recovering from this type of lymphoma, the thymus gland can reactivate after chemotherapy, showing up on imaging as what appears to be active disease. Given his age and specific scan characteristics, the model put the probability of that explanation at roughly 90%. He sought three more opinions. The fourth doctor confirmed it: thymus rebound. No active disease. No radiotherapy needed. He was clear.
What the experience taught him about the system
Christou is still unfolding what the last year has meant. He built Keragon, his current company, before any of this happened; it’s an AI-powered platform that helps medical practices automate administrative operations. But going through the system as a patient gave him new perspective. He watched nurses and doctors buried under tasks that had nothing to do with care. He received the same chemotherapy protocol as an 80-year-old woman, the side effects managed through a cascading chain of additional drugs, each causing problems of their own.
He says he’s certain that we will look back at this era of treatment and cringe.
He takes Sundays off now, mostly. He tries to be present — at lunch with friends, at home with his dog, in conversations that might once have felt like a distraction from work. A VC friend told him something years ago that he kept replaying during treatment: Be happy now. He says it’s among the hardest things to do and yet he finally appreciates its importance.
“It’s not happening in 10 years,” he said of what AI can already do for patients willing to use it. “It’s happening today.”
FAQs
Q1: Is it safe to use AI chatbots for medical advice?
Experts caution that general-purpose AI models are not evaluated for personalized diagnoses and can be wrong. They are best used as a tool to help patients ask better questions and understand medical literature, not as a replacement for professional medical advice.
Q2: How common is the type of lymphoma Christou had?
His specific aggressive form of non-Hodgkin’s lymphoma affects roughly one in 420,000 people. It is caused by a random genetic mutation with no known link to lifestyle, diet, or stress.
Q3: What is thymus rebound and why does it matter?
Thymus rebound is a benign reactivation of the thymus gland that can occur in younger patients after chemotherapy. It can appear on PET scans as active disease, leading to a false-positive rate of around 60% for certain lymphomas. Recognizing it can prevent unnecessary additional treatment like radiotherapy.
Disclaimer: The information provided is not trading advice, Bitcoinworld.co.in holds no liability for any investments made based on the information provided on this page. We strongly recommend independent research and/or consultation with a qualified professional before making any investment decisions.
